Skip to main content
Clinical Trials/EUCTR2021-005552-11-Outside-EU/EEA
EUCTR2021-005552-11-Outside-EU/EEA
Active, not recruiting
Phase 1

A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa.

Genzyme Corporation0 sitesMarch 7, 2022

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Pompe disease
Sponsor
Genzyme Corporation
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2022
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • The patient's legal guardian must provide signed, informed consent prior to performing any study\-related procedures;
  • The patient must have a confirmed diagnosis of Pompe disease as determined by deficient endogenous acid alpha\-glucosidase (GAA) activity or GAA mutation analysis; and
  • The patient must be \<1 year of age at time of study enrollment (and receive alglucosidase alfa treatment before 1 year of age), or the patient must be between 1 year and 24 months of age and must have initiated alglucosidase alfa treatment prior to turning 1 year of age.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 15
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • The patient is participating in another clinical study using alglucosidase alfa or any investigational therapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials